666 related articles for article (PubMed ID: 28193515)
21. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.
Checkley LA; Kristofek L; Kile S; Bolgar W
Dig Dis Sci; 2019 Mar; 64(3):855-862. PubMed ID: 30311152
[TBL] [Abstract][Full Text] [Related]
22. Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort.
Chanchlani N; Mortier K; Williams LJ; Muhammed R; Auth MKH; Cosgrove M; Fagbemi A; Fell J; Chong S; Zamvar V; Hyer W; Bisset WM; Morris MA; Rodrigues A; Mitton SG; Bunn S; Beattie RM; Willmott A; Wilson DC; Russell RK
J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):513-519. PubMed ID: 29697550
[TBL] [Abstract][Full Text] [Related]
23. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
Hanauer SB; Sandborn WJ; Lichtenstein GR
Gastroenterology; 2019 Jan; 156(1):36-42. PubMed ID: 30195449
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Clinical Outcomes After Switching from Remicade
Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
[TBL] [Abstract][Full Text] [Related]
25. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.
Andrade P; Santos-Antunes J; Rodrigues S; Lopes S; Macedo G
J Gastroenterol Hepatol; 2015 Nov; 30(11):1591-5. PubMed ID: 25967740
[TBL] [Abstract][Full Text] [Related]
26. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
27. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate for inflammatory bowel disease: time for reconsideration.
Nielsen OH; Ainsworth MA; Steenholdt C
Expert Rev Gastroenterol Hepatol; 2019 May; 13(5):407-409. PubMed ID: 30895827
[No Abstract] [Full Text] [Related]
29. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
Merras-Salmio L; Kolho KL
J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
[TBL] [Abstract][Full Text] [Related]
30. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
[TBL] [Abstract][Full Text] [Related]
31. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.
Lichtenstein GR; Rutgeerts P; Sandborn WJ; Sands BE; Diamond RH; Blank M; Montello J; Tang L; Cornillie F; Colombel JF
Am J Gastroenterol; 2012 Jul; 107(7):1051-63. PubMed ID: 22613901
[TBL] [Abstract][Full Text] [Related]
32. Hemophagocytic lymphohistiocytosis in inflammatory bowel disease: a nationwide analysis.
Mahmoud AA; Abdelhay A; Khamis A; Mostafa M; Shehadah A; Mohamed MS; Eltaher B; Malik T
Ann Hematol; 2023 Jul; 102(7):1705-1711. PubMed ID: 37093242
[TBL] [Abstract][Full Text] [Related]
33. Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease.
Hradsky O; Copova I; Zarubova K; Durilova M; Nevoral J; Maminak M; Hubacek P; Bronsky J
Dig Dis Sci; 2015 Nov; 60(11):3399-407. PubMed ID: 26091801
[TBL] [Abstract][Full Text] [Related]
34. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
Kim NH; Lee JH; Hong SN; Yoon H; Kang HW; Lee SH; Im JP; Cha JM; Eun CS; Kim JW; Choi CH; Park DI
J Gastroenterol Hepatol; 2019 Sep; 34(9):1523-1532. PubMed ID: 30828891
[TBL] [Abstract][Full Text] [Related]
35. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases.
Jung ES; Choi KW; Kim SW; Hübenthal M; Mucha S; Park J; Park Z; Ellinghaus D; Schreiber S; Franke A; Oh WY; Cheon JH
J Gastroenterol Hepatol; 2019 Oct; 34(10):1727-1735. PubMed ID: 30851117
[TBL] [Abstract][Full Text] [Related]
36. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
Schnitzler F; Fidder H; Ferrante M; Ballet V; Noman M; Van Assche G; Spitz B; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Inflamm Bowel Dis; 2011 Sep; 17(9):1846-54. PubMed ID: 21830263
[TBL] [Abstract][Full Text] [Related]
37. Clinical predictors of thiopurine-related adverse events in Crohn's disease.
Moran GW; Dubeau MF; Kaplan GG; Yang H; Eksteen B; Ghosh S; Panaccione R
World J Gastroenterol; 2015 Jul; 21(25):7795-804. PubMed ID: 26167079
[TBL] [Abstract][Full Text] [Related]
38. Risk and clinical characteristics of lymphoma in Korean patients with inflammatory bowel diseases: a multicenter study.
Park SK; Ye BD; Lee C; Im JP; Kim YH; Kim SO; Byeon JS; Myung SJ; Yang SK; Kim JH
J Clin Gastroenterol; 2015 Feb; 49(2):e11-6. PubMed ID: 24705089
[TBL] [Abstract][Full Text] [Related]
39. The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World.
Church PC; Hyams J; Ruemmele F; de Ridder L; Turner D; Griffiths AM
Can J Gastroenterol Hepatol; 2018; 2018():3190548. PubMed ID: 30009157
[TBL] [Abstract][Full Text] [Related]
40. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
